Salix Pharmaceuticals has agreed to acquire privately held Oceana Therapeutics for US$300 M in cash in order to gain access to its two marketed therapies, Solesta® for faecal incontinence and Deflux® for vesicoureteral reflux. The deal, which is expected to close before the end of 2011, will provide revenue growth for the company. Indeed, in the hands of its speciality sales force, Salix believes that Solesta, which was approved by the US FDA in May 2011, could achieve peak year sales of more than US$500 M.